GlassScriptPhysician profile
John A Henderson
NPI 1255337051
$3,091.75
in general payments reported to CMS, 2019-2025
31 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $113 · 2021: $269 · 2022: $576 · 2023: $497 · 2024: $526 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.38 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.38 | 2019-2025 | |
| Astellas Pharma US INC | $493.00 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $347.64 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $254.10 | 2020-2025 | Axonics, Spaceoar Vue System - 10ml |
| Procept Biorobotics Corporation | $157.21 | 2019-2025 | Aquabeam Robotic System |
| Ferring Pharmaceuticals INC. | $149.10 | 2019-2025 | Adstiladrin |
| Allergan, INC. | $138.77 | 2019-2022 | |
| Caris Mpi, INC. | $117.97 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $111.61 | 2019-2024 | Erleada |
| Endo Pharmaceuticals INC. | $95.71 | 2020-2023 | Aveed, Xiaflex |
| Laborie Medical Technologies Corp. | $94.49 | 2023-2025 | |
| Coloplast Corp | $78.26 | 2019-2023 | Altis |
| Travere Therapeutics, INC. | $59.54 | 2020-2021 | |
| Urovant Sciences INC | $58.78 | 2021-2022 | |
| Tolmar, INC. | $55.26 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $48.72 | 2023 | Evarrest |
| Myovant Sciences INC. | $47.29 | 2021-2022 | |
| Heron Therapeutics, INC. | $27.85 | 2024 | Zynrelef |
| Teleflex LLC | $27.10 | 2022 | |
| Stryker Corporation | $24.46 | 2022 | |
| Accord Healthcare, INC. | $21.57 | 2025 | |
| Axonics, INC. | $21.18 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $19.73 | 2025 | Keytruda |
| Acacia Pharma INC | $19.09 | 2022 | |
| Pfizer INC. | $18.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.08 | 2022 | |
| Cycle Pharmaceuticals INC | $17.57 | 2024 | Tiopronin |
| Immunitybio, INC. | $15.85 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $14.29 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.35 | 2019 | |
| Kerecis Limited | $9.63 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.